Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer Carbonate in Pediatric Hyperphosphatemia with CKD
NCT01574326Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2012
- Primary completion
- Jun 2015
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in hyperphosphatemia comparing Placebo -> Sevelamer with Sevelamer -> Sevelamer (2 arms). Primary endpoints: Change From Baseline to Week 2 in Serum Phosphorus and Treatment-Emergent Adverse Events at 32 weeks. Started May 2012; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01574326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01574326.